2026-09-07 Posted by TideChem view:94
Glucagon-like peptide-1, usually abbreviated as GLP-1, is a peptide hormone involved in glucose regulation, gastric emptying and appetite signaling. It is released mainly from intestinal L cells after food intake and activates the GLP-1 receptor in the pancreas, gastrointestinal tract, nervous system and other tissues.
Native GLP-1 has several biologically useful effects, but it is rapidly degraded in the body. Its circulating half-life is commonly reported as approximately one to five minutes. This instability initially limited its value as a medicine, but it also created an important opportunity for peptide drug development.
By modifying the amino acid sequence, attaching fatty-acid side chains or using larger carrier structures, developers have transformed the short-lived natural hormone into longer-acting therapeutic molecules. GLP-1 is therefore more than a metabolic hormone. It is an instructive example of how sequence engineering, conjugation chemistry and formulation science can convert a fragile endogenous peptide into a viable drug platform.
GLP-1 is produced from proglucagon, a larger precursor protein encoded by the GCG gene. Tissue-specific processing determines which hormones are released from this precursor.
In intestinal L cells, prohormone convertase 1/3 processes proglucagon into several peptides, including GLP-1, GLP-2, oxyntomodulin and glicentin-related products. Nutrients such as carbohydrates, fats and proteins stimulate GLP-1 secretion.
The two principal biologically active forms are:
GLP-1(7-36) amide is generally considered the predominant circulating active form.
Its amino acid sequence is:
His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH₂
GLP-1(7-37) contains one additional glycine at the C-terminus. The biological numbering begins at residue 7 because GLP-1 is released from a larger proglucagon sequence. PubChem GLP-1 sequence
GLP-1 acts by binding to the GLP-1 receptor, or GLP-1R. This receptor belongs to the class B family of G protein-coupled receptors.
After receptor activation, intracellular cyclic AMP levels increase. Downstream signaling through protein kinase A and other pathways contributes to several physiological effects.
GLP-1 enhances insulin secretion from pancreatic beta cells when blood glucose is elevated. This glucose dependence is pharmacologically important because the response becomes weaker as glucose concentrations fall.
GLP-1 can reduce inappropriate glucagon secretion when glucose is elevated. Lower glucagon signaling reduces hepatic glucose output and supports glucose control.
GLP-1 can slow the movement of food from the stomach into the small intestine. This changes the rate at which nutrients, particularly glucose, enter the circulation.
The strength and duration of this effect can vary with the molecule, exposure pattern and length of treatment.
GLP-1 receptor signaling in the gastrointestinal and nervous systems contributes to increased satiety and reduced food intake. These effects helped establish GLP-1R as a therapeutic target for both type 2 diabetes and chronic weight management.
A detailed physiological overview is available through NCBI Endotext.
The principal limitation is rapid enzymatic degradation.
Dipeptidyl peptidase-4, or DPP-4, recognizes the N-terminal region of GLP-1 and removes the His7-Ala8 dipeptide. This produces GLP-1(9-36) amide or the corresponding 9-37 form, which has greatly reduced classical GLP-1 receptor agonist activity.
Additional degradation and clearance involve neutral endopeptidases, the liver and the kidneys. Only a small proportion of secreted intact GLP-1 reaches the systemic circulation.
Native GLP-1 therefore presents several development problems:
Solving these problems requires more than increasing peptide purity. Developers must redesign the molecule or its delivery system.
GLP-1 demonstrates how different drug-design technologies can address separate weaknesses of the same peptide.
A successful GLP-1 analogue must balance:
A structural change that improves one property may weaken another. Stronger albumin binding can prolong exposure but may lower the free concentration available for receptor binding. Increased hydrophobicity can support half-life extension while creating solubility and aggregation problems.
GLP-1 development is therefore a multidimensional optimization problem rather than a simple exercise in maximizing receptor potency.
The N-terminus is essential for GLP-1 receptor activation, but it is also the region attacked by DPP-4. A substitution at or near position 8 can improve enzymatic stability.
Semaglutide, for example, contains 2-aminoisobutyric acid, or Aib, at position 8 instead of alanine. Aib is a non-proteinogenic amino acid that improves resistance to DPP-4 cleavage.
This substitution must be designed carefully. The GLP-1 N-terminus enters the transmembrane region of the receptor and plays a direct role in activation. Large structural changes can produce a stable peptide with weak agonist activity.
Lipidation is one of the most important half-life extension strategies used in GLP-1 drug development.
A fatty acid is typically attached to a lysine side chain through a defined linker. The lipid group supports reversible association with serum albumin, which can reduce renal filtration and protect the peptide from enzymatic degradation.
Examples include liraglutide and semaglutide, although their side-chain structures and pharmacokinetic profiles differ.
Variables that require optimization include:
Lipidation can also promote oligomerization or aggregation. A recent study of lipidated GLP-1 analogues found that lipidation affected solubility, secondary structure and oligomer formation, highlighting the connection between molecular design and formulation behavior. PubMed
PEGylation attaches a polyethylene glycol chain to a selected amino acid side chain or peptide terminus.
Potential benefits include:
PEGylation is a useful development strategy, but it is not automatically suitable for every GLP-1 analogue. A PEG chain positioned too close to a receptor-binding surface may reduce potency. Polydisperse PEG can also complicate characterization, while monodisperse PEG derivatives provide a more precisely defined molecular structure.
PEGylation has been investigated alongside lipidation, albumin fusion, Fc fusion and sustained-release systems as a GLP-1 half-life extension technology. Review of GLP-1 delivery technologies
GLP-1 analogues can be fused to larger proteins or protein domains, including albumin or an immunoglobulin Fc region.
Increasing molecular size reduces renal clearance and may support recycling through the neonatal Fc receptor pathway. These approaches can produce prolonged exposure but require recombinant manufacturing and protein-specific analytical controls.
Developers must evaluate:
Instead of modifying only the peptide, developers may control how quickly it is released from the dosage form.
Microspheres, implants and other depot systems can extend apparent exposure. However, the peptide must remain stable during manufacturing, storage and release.
Local pH changes, moisture, polymer degradation products and elevated processing temperatures may lead to oxidation, deamidation, aggregation or incomplete release.
GLP-1R uses a two-region recognition mechanism typical of class B GPCRs. The central and C-terminal portions of GLP-1 interact with the extracellular receptor domain, while the peptide N-terminus engages the transmembrane region and activates signaling.
This has practical consequences for analogue design:
Structural studies of GLP-1R have shown how the peptide occupies the receptor-binding pocket and stabilizes an active receptor conformation. Nature study indexed by PubMed
GLP-1 analogue synthesis may require more than the 20 standard amino acids. Common building-block classes include:
Orthogonal lysine protection is particularly important for site-specific lipidation. The selected protecting group must survive peptide-chain assembly but be removable without damaging the remaining sequence.
Building-block quality directly affects the final impurity profile. Incorrect stereochemistry, partially protected material or unstable activated derivatives can produce impurities that become difficult to separate after full peptide assembly.
GLP-1 analogues can be manufactured by solid-phase peptide synthesis, recombinant expression or a hybrid process.
SPPS provides direct control over non-natural amino acids, sequence substitutions and site-specific protecting groups. It is useful for analogue screening and many synthetic peptide APIs.
Challenges include:
Recombinant methods can efficiently generate peptide backbones or larger fusion proteins. Their limitations include constraints on non-natural amino acid incorporation and the need to control host-cell proteins, nucleic acids and other process-related impurities.
A recombinant precursor may be produced first and then chemically modified through lipidation or another conjugation reaction. Semaglutide manufacturing is an example of a recombinant peptide backbone followed by chemical modification and purification. EMA assessment report
Hybrid manufacturing combines the advantages of biosynthesis and chemical conjugation but requires strong control of intermediates, modification efficiency and residual unmodified precursor.
A potent and long-acting analogue is not yet a finished drug. Formulation determines whether the molecule remains stable, soluble and deliverable throughout its shelf life.
Important development variables include:
Lipidated analogues may exhibit limited solubility within certain pH ranges. Highly concentrated formulations can also promote self-association or aggregation.
Forced-degradation studies should distinguish chemical instability from physical instability. Chemical testing may monitor oxidation, deamidation and hydrolysis, while physical studies examine particles, aggregation, precipitation and changes in secondary structure.
Oral peptide delivery is difficult because peptides are degraded in the gastrointestinal tract and generally cross the intestinal epithelium poorly.
Oral semaglutide demonstrates that oral delivery can be achieved with a suitable formulation and absorption-enhancing strategy. However, the bioavailability of oral peptide formulations remains much lower and more variable than that of many small molecules.
Developers working on oral GLP-1 systems must consider:
An oral formulation should not be evaluated only by whether measurable absorption occurs. Variability, safety, manufacturability and patient-use conditions are equally important.
A GLP-1 analogue requires orthogonal analytical methods because a single HPLC result cannot establish identity, purity and biological function.
A suitable control strategy may include:
For lipidated peptides, testing should distinguish the intended conjugate from unmodified peptide, positional isomers, incomplete linkers and related lipid variants.
Immunogenicity risk may also be influenced by aggregates and product-related impurities. The FDA recommends integrating immunogenicity assessment with the broader clinical pharmacology program for peptide drug products. FDA peptide guidance
A building block that is suitable for analogue screening may not be practical for commercial manufacture.
Before candidate selection, developers should evaluate:
Early process assessment can prevent a project from becoming dependent on a rare intermediate with poor yield or an uncontrolled impurity profile.
According to its published product and company information, Tide Chem supplies protected and non-natural amino acids, short peptides, monodisperse PEG derivatives and long-acting peptide side-chain building blocks. These material classes are relevant to GLP-1 analogue screening, linker optimization, lipidation and process development.
Tide Chem also describes capabilities in:
The company states that it operates QC and QA functions, maintains an ICH-aligned laboratory quality system and has obtained ISO 9001 certification. These company-level credentials do not replace product-specific qualification. Development teams should still evaluate the specification, manufacturing status, analytical package and change-control arrangements for each material. Tide Chem About Us, Tide Chem Quality Assurance
A specialty manufacturer should ideally be engaged before the final analogue is selected when a project depends on custom Aib derivatives, orthogonally protected lysine, monodisperse PEG spacers or complex fatty-diacid side chains.
No. Both are produced from proglucagon, but they are distinct hormones with different receptor targets and physiological functions.
GLP-1(7-36) amide contains 30 amino acid residues. GLP-1(7-37) contains 31 residues.
Its N-terminus is rapidly cleaved by DPP-4. Additional enzymatic degradation and renal and hepatic clearance also limit systemic exposure.
No. Therapeutic GLP-1 receptor agonists use different peptide backbones and half-life extension technologies. Some are based closely on human GLP-1, while others are related to exendin-4 or use fusion-protein designs.
Tirzepatide activates both GIP and GLP-1 receptors. It belongs to the broader incretin therapeutic field but is not a selective GLP-1-only analogue.
It is one available method. Fatty-acid conjugation, sequence modification, Fc fusion, albumin fusion and sustained-release delivery are also important strategies.
Glucagon-like peptide-1 is an intestinal peptide hormone that supports glucose-dependent insulin secretion, regulates glucagon, slows gastric emptying and contributes to satiety signaling. Its biological activity makes GLP-1R an important therapeutic target, but native GLP-1 is too rapidly degraded to function as a convenient long-acting medicine.
For peptide drug developers, GLP-1 provides a clear model of rational molecular engineering. Non-natural amino acids can improve resistance to DPP-4, fatty-acid side chains can promote albumin binding, PEG derivatives can alter clearance and solubility, and larger fusion partners can extend systemic exposure.
The most successful development strategy balances receptor potency with stability, solubility, manufacturability and analytical control. Early coordination between discovery scientists, formulation teams, process chemists and qualified raw-material suppliers is essential for translating a promising GLP-1 sequence into a scalable therapeutic candidate.